Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- City Therapeutics Announces Pricing of Upsized Initial Public OfferingCompanies: Jefferies Financial GroupCity Therapeutics Announces Pricing of Upsized Initial Public Offering
- ŌURAŌURA Announces Launch of Initial Public OfferingCompanies: Jefferies Financial GroupMorgan StanleySAN FRANCISCO, September 21, 2026--ŌURA, a leading health intelligence platform and maker of the world’s smallest smart ring, today announced that it has launched its initial public offering of 50,000,000 shares of its common stock. The offering consists of 13,500,000 shares offered by Oura and 36,500,000 shares offered by certain of Oura’s existing stockholders. In addition, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 7,500,000 share
- CoVolt Power, Inc.CoVolt Power Announces Public Filing of Registration Statement for Proposed Initial Public OfferingCompanies: Jefferies Financial GroupHOUSTON, August 21, 2026--CoVolt Power, Inc. ("CoVolt Power" or the "Company"), today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of shares of its Class A common stock.
- Ares Acquisition Corporation IIIAres Acquisition Corporation III Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing August 20, 2026Companies: Jefferies Financial GroupNEW YORK, August 20, 2026--Ares Acquisition Corporation III (NYSE: AAC.U) (the "Company"), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, today announced that, commencing August 20, 2026, holders of the 39,500,000 units sold in the Company’s initial public offering (the "Units"), completed on July 1, 2026, may elect to separately trade the Class A ordinary shares and warrants included in the Units. Those Units not separate
- Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSsCompanies: Jefferies Financial GroupMorgan StanleyLONDON, August 14, 2026--Silence Therapeutics plc, (Nasdaq: SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the closing of its previously announced underwritten public offering of 14,907,407 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS, which incl